HealthMed Holdings has finished validating its new Myocardial Assessment Profile (MAP) test for the detection of heart attack risk. The simple blood test is intended to detect risks that might be overlooked by other diagnostics in individuals with normal cholesterol and no cardiac symptoms.
The Doha, Qatar, devicemaker said Thursday it will market the test available globally, targeting countries where heart disease, obesity and diabetes are on the rise.
The MAP test measures compounds in the blood that are commonly involved in vascular inflammation, potentially heading off a heart attack in unsuspecting individuals. The diagnostic allows physicians to treat patients according to new American Heart Association/American College of Cardiology guidelines, which encourage preventive care, HealthMed said.
According to the company, inflammation is responsible for up to 75 percent of heart attacks worldwide, making it the most common cause of such events. — Lena Freund
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.